BRBR vs. BIO.B, VKTX, CERE, LEGN, PEN, PCVX, BIO, ASND, ELAN, and GMED
Should you be buying BellRing Brands stock or one of its competitors? The main competitors of BellRing Brands include Bio-Rad Laboratories (BIO.B), Viking Therapeutics (VKTX), Cerevel Therapeutics (CERE), Legend Biotech (LEGN), Penumbra (PEN), Vaxcyte (PCVX), Bio-Rad Laboratories (BIO), Ascendis Pharma A/S (ASND), Elanco Animal Health (ELAN), and Globus Medical (GMED). These companies are all part of the "medical" sector.
BellRing Brands (NYSE:BRBR) and Bio-Rad Laboratories (NYSE:BIO.B) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.
In the previous week, BellRing Brands had 15 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 16 mentions for BellRing Brands and 1 mentions for Bio-Rad Laboratories. BellRing Brands' average media sentiment score of 0.51 beat Bio-Rad Laboratories' score of 0.42 indicating that BellRing Brands is being referred to more favorably in the media.
95.0% of BellRing Brands shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 0.8% of BellRing Brands shares are owned by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
BellRing Brands has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
BellRing Brands has a net margin of 10.39% compared to Bio-Rad Laboratories' net margin of -12.37%. Bio-Rad Laboratories' return on equity of 3.59% beat BellRing Brands' return on equity.
Bio-Rad Laboratories received 10 more outperform votes than BellRing Brands when rated by MarketBeat users. However, 67.25% of users gave BellRing Brands an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.
BellRing Brands presently has a consensus target price of $61.83, indicating a potential upside of 6.21%. Given BellRing Brands' higher probable upside, research analysts plainly believe BellRing Brands is more favorable than Bio-Rad Laboratories.
BellRing Brands has higher earnings, but lower revenue than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than BellRing Brands, indicating that it is currently the more affordable of the two stocks.
Summary
BellRing Brands beats Bio-Rad Laboratories on 13 of the 17 factors compared between the two stocks.
Get BellRing Brands News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRBR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BellRing Brands Competitors List
Related Companies and Tools
